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http://dx.doi.org/10.1016/j.bgm.201Abstract Drug resistance is a key contributor for treatment failure in hematologic and other
malignancies. Nilotinib has been observed with significant activity in patients with chronic
phase chronic myeloid leukemia (CML) who have failed or are intolerant of imatinib therapy.
Recent reports have suggested that microRNA (miRNA) expression changes are involved in
the drug response of human cancer. Several miRNAs have been previously found to be consis-
tently deregulated in imatinib resistance; however, very limited information is available for
nilotinib-treated patients who have failed imatinib therapy. Many reports have discovered
circulating miRNAs as noninvasive biomarkers of disease and therapy response. The aim of this
study was to explore miRNA regulation and find candidate miRNA markers for CML that can be
used for drug response prediction. Here we demonstrate the circulating miRNA profile in the
culture supernatant of imatinib-resistant K562 CML cells (K562-R) by microarray chip analysis.
We have identified specific miRNAs that are associated with nilotinib sensitivity by comparison
of miRNA expression patterns from the culture supernatant of nilotinib-treated K562-R cells
with the culture supernatant of untreated K562-R cells. The information obtained from thisHematology/Oncology, Department of Internal Medicine, Taipei Medical UniversityeShuang-Ho
ad, Zhonghe District, New Taipei City 23561, Taiwan.
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72 R.-I. You et al.Table 1 The expression pattern
MicroRNA Up-/downre
level
miR-221 3.327
miR-379 0.504
miR-548 0.132
miR-603 0.229
miR-658 0.340study may have the potential to become a novel biomarker to predict drug response in the
future and can also be applied to developing novel therapeutic treatment for CML.
Copyright ª 2013, Taiwan Genomic Medicine and Biomarker Society. Published by Elsevier
Taiwan LLC. All rights reserved.Introduction
Treatment with imatinib (the BCR-ABL tyrosine kinase in-
hibitor) has been established as the standard therapy for
chronic myeloid leukemia (CML), which has a significantly
cytogenetic response in more than 75% of newly diagnosed
patients with chronic phase CML.1 Despite the high effi-
ciency of imatinib therapy, approximately 30% of patients
develop resistance to imatinib, resulting in first-line ther-
apy failure.2 Although it is possible to use molecular anal-
ysis by polymerase chain reaction (PCR) to detect
molecular response with prognostic implication, there are
other genetic or epigenetic alterations that may contribute
to CML stem cells survival during a long-term tyrosine ki-
nase inhibitor (TKI) therapy that successfully inhibits the
BCR-ABL activity but is not curative.3 The existence of
second-generation tyrosine kinase inhibitors (nilotinib and
dasatinib), which are effective in patients with imatinib
resistance, makes identification of predictors of resistance
to imatinib an important goal in CML.4 The expression
profiling of microRNAs (miRNAs) has been performed as a
potential method for cancer subtype classification with
prognostic value and to estimate the success of anticancer
treatment.5 miRNAs are small single-stranded noncoding
RNA molecules with lengths of 17e25 nucleotides that
affect the stability of mRNAs and suppress protein trans-
lation through interacting complementary target sites in
the 30 untranslated region of target mRNAs.6 Dysregulation
of miRNA expression via genomic abnormalities, chromatin
modifications, transcriptional regulation, and abnormal
biogenesis are observed in various cancer types, tumor
metastasis, and drug resistance.7 In CML, several miRNAs
(miR-15a, miR-16, miR-17e92 cluster, miR-142, miR-155,
miR-181, miR-221, and let7a) have been described with
abnormal expression patterns.8 Downregulation of miR-10a
has been reported with abnormal proliferation of CML cells
through the regulation of USF2 gene expression.9 In addi-
tion, low expression of miR-144/451 has been associated
with imatinib response in CML.10 These reports indicate
that alternations of miRNA expression might be involved in
tumor progression and drug resistance development.s of microRNA up-/downregulat
gulation No. of gene
conserved
(from Targe
446
94
659
413
15Materials and methods
Imatinib-resistant K562-R cells were derived as previously
described.11 Cells were grown in RPMI-1640 medium supple-
mentedwith 10% heat-inactivated fetal bovine serum (GIBCO,
Grand Island, NY, USA), 2 mM glutamine, and 1% penicillin/
streptomycin (Invitrogen, Carlsbad, CA, USA) containing
2.5 mM imatinib (Gleevec; Novartis Pharma, Basel,
Switzerland). The culture mediumwas collected from K562-R
cells exposed to 5 nmol/L nilotinib (Novartis Pharma) and
centrifuged at 3000  g for 15 minutes. The supernatant was
filtered through a 0.22-mmPVDF filter (Millipore, Bedford,MA,
USA). Extracellular and intracellular miRNAs were extracted
from K562-R cells and the supernatant described above using
the mirVana Paris kit (Invitrogen) according to the manufac-
turer’s instructions. The miRNA microarray was performed
using the Agilent Human miRNA Microarray (Agilent Technol-
ogy, Santa Clara, CA, USA). miRNA microarray results were
analyzed using the GeneSpring GX software (Agilent Tech-
nology).12 The TaqMan miRNA assays (Applied Biosystems,
Foster City, CA, USA) was used to detect and quantify the
expression level of individual miRNAs by real-time quantita-
tive PCR (qPCR). cDNA was synthesized using the Taqman
miRNA RT Kit (Applied Biosystems), and the relative quanti-
ties of intracellular miRNA were calculated using the
comparative Ct methods after normalization to hsa-miR-92a
(000431). Statistical significance was analyzed with the
GraphPad Prism software (GraphPad Software Inc., San Diego,
CA, USA). A p value <0.05 was considered statistically sig-
nificant. The biological targets of miRNAs were predicted
using TargetSpy, TargetScan, miRanda, and PicTar.Results
The results from miRNA microarray analysis revealed a
number of extracellular miRNAs that were differentially
regulated in the culture supernatant of nilotinib-treated
K562-R cells as compared to untreated control. A subset of
miRNAs was selected to further validate the miRNA micro-
array data. We identified five miRNAs with statisticallyed in nilotinib-treated K562-R cells.
s of possible
targets
tScan)
Mature miRNA sequence
AGCUACAUUGUCUGCUGGGUUUC
UGGUAGACUAUGGAACGUA
AAAAGUAAUUGCGGAUUUUGCC
CACACACUGCAAUUACUUUUGC
GGCGGAGGGAAGUAGGUCCGUUGGU
Nilotinib-altered miRNAs in imatinib-resistant CML cells 73significant differential expression between nilotinib-
treated and untreated cells. The expression level of one
of them was upregulated, and four of them were down-
regulated in nilotinib-treated K562-R cells (Table 1).
Discussion
In this study, there was a significant difference in the fold
change of the expression level of circulating miRNAs in
nilotinib-treated K562-R cells by miRNA microarray. We
selectively confirmed five miRNAs with statistically signifi-
cant differential expression by miRNA qPCR. These results
implicated that cell-free miRNAs could be a potential source
of drug response prediction. Further comparison of intra-
cellular miRNAs with extracellular miRNA expression pat-
terns will clarify these regulatory miRNA networks with
various targets in disease condition. Furthermore, compari-
son of the expression profilewith plasma or serummiRNAwill
be important to understand clinical use application.13
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